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3ABSTRACT 
Type  1  diabetes  is  an  autoimmune  condition  caused  by  the  lymphocyte-mediated
destruction of the insulin-producing  β cells in pancreatic islets. We aimed to identify
final molecular entities targeted by the autoimmune assault on pancreatic β cells that are
causally related to  β cell viability.  Here, we show that cyclin D3 is targeted by the
autoimmune attack on pancreatic β cells in vivo.  Cyclin D3 is downregulated in a dose-
dependent manner in  β cells by leukocyte infiltration into the islets of the Non-Obese
Diabetic (NOD) Type 1 diabetes-prone mouse model.  Furthermore, we established a
direct  in vivo causal link between cyclin D3 expression levels and  β cell fitness and
viability in the NOD mice. We found that changes in cyclin D3 expression levels in vivo
altered  the  β cell  apoptosis  rates,  β cell  area  homeostasis,  and  β cell  sensitivity to
glucose without affecting  β cell  proliferation in the NOD mice.  Cyclin D3-deficient
NOD  mice  exhibited  exacerbated  diabetes  and  impaired  glucose  responsiveness;
conversely, transgenic NOD mice overexpressing cyclin D3 in  β cells exhibited mild
diabetes and improved glucose responsiveness. Overexpression of cyclin D3 in β cells
of cyclin D3-deficient mice rescued them from the exacerbated diabetes observed in
transgene-negative littermates. Moreover, cyclin D3 overexpression protected the NOD-
derived insulinoma NIT-1 cell line from cytokine-induced apoptosis. Here, for the first
time, cyclin D3 is identified as a key molecule targeted by autoimmunity that plays a
non-redundant,  protective  and  cell-cycle  independent  role  in  β cells  against
inflammation-induced apoptosis and confers metabolic fitness to these cells.
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SIGNIFICANCE STATEMENT
Autoimmune  diabetes  is  caused  by  the  lymphocyte-mediated  destruction  of  the
pancreatic insulin-producing β cells. The inflammatory niche surrounding β cells prior
to diabetes onset provokes death-inducing molecular changes in these cells. Unknown
molecular pathways related to β cell viability that are altered by inflammation in vivo,
and, therefore, potential therapeutic targets, remain to be identified, since most of the
previous studies took  in vitro  approaches. Here, we report that cyclin D3, classically
related to cell proliferation, is targeted in autoimmune diabetes and exerts a protective
role on β cells, by promoting their survival and fitness without affecting proliferation.
These  findings  unveil  a  dual,  cell  cycle-independent  role  of  cyclin  D3  with  high
potential in the areas of autoimmunity and metabolism.
5\body 
INTRODUCTION
Apoptosis is the major cause of pancreatic  β cell death in autoimmune diabetes
(Type 1 diabetes or T1D) (1-9). The inflammatory infiltration into pancreatic islets in
T1D provokes a large number of cell-death-inducing molecular changes in β cells. Pro-
inflammatory cytokines trigger the activation and translocation of transcription factors
into  the  nucleus,  the  induction  of  target  gene  transcription  (10),  and  the  post-
translational modification of proteins in β cells (3, 11).  
Previously,  several  approaches  have  been  taken  to  address  differential  gene
expression in β cells due to pro-inflammatory cytokines (10, 12, 13). Nonetheless, those
studies focused on molecular targets, the expression of which was altered in islets or β
cell lines upon  in vitro incubation with proinflammatory cytokines (e.g., IL-1β, IFNγ
and  TNFα) (10,  12-13).  That  type  of  study  does  not  account  for  the  in  vivo
microenvironment  to  which  β cells  are  exposed  in  animals  with  autoimmune-prone
genetic  backgrounds,  such  as  the  Non-Obese  Diabetic  (NOD) mouse  model,  which
surely comprises more factors than the above mentioned cytokines. Therefore, potential
targets involved in β cell death remain to be identified. 
We found that  in NOD mice,  cyclin D3 (CcnD3 gene) mRNA expression was
impaired in endocrine cells  from heavily infiltrated pancreatic  islets (see Supporting
Information Table 1).  The cyclin D3 promoter contains binding sequences for the NF-
kB transcription factor (14). IL-1β and TNFα are key cytokines causing β cell damage
in T1D, and NF-kB is linked to the action of both cytokines (3). Therefore, cyclin D3
could be downregulated in β cells by the action of NFκB.  
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Cell cycle entry in mammal eukaryotic cells is coordinated by D-type cyclins D1,
D2 and D3 (15, 16). Cyclins D1 and D3 are involved in cell cycle progression in a CDK
(cyclin  dependent  kinase)-dependent  manner,  in  CDK-independent  activation  of
transcription,  and  in  metabolic  control  (17-21).   Therefore,  cyclin  D3  might  play
unknown roles in pancreatic β cells which could explain why cyclin D3 downregulation
is associated with T1D.
Cyclin D3-deficient mice with a non autoimmune-prone genetic background do
not exhibit pancreatic β cell hypoplasia, which implies that cyclin D3 is not required for
β cell mass generation in adult individuals (22, 23).  Moreover, two previous reports
using other non autoimmune-prone mouse strains did not detect significant cyclin D3
expression in pancreatic islets (23, 24). To address whether a causal link exists between
cyclin  D3 downregulation  in  autoimmune diabetes  in  NOD mice  upon the  insulitic
attack  and  autoimmune  diabetes,  we  first  assessed  cyclin  D3  expression  levels  in
pancreatic  β cells   from  the  autoimmune-prone  NOD  and  NOD/SCID  genetic
backgrounds. Next, we developed NOD mice ubiquitously deficient in cyclin D3, NOD
mice that overexpressed cyclin D3 locally in  β cells, and a combination of both, i.e.
cyclin  D3-deficient  NOD  mice  overexpressing  cyclin  D3  solely  in  β cells.  We
characterized these mice with regard to autoimmune diabetes and β cell function. 
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Cyclin D3 is downregulated in β cells by the insulitic attack without impairing β cell
proliferative activity.
Previous  results  from  microarrays  studies  from  our  lab  (see  Supporting
Information Table 1) found that cyclin D3 mRNA expression levels were almost three-
fold reduced in pancreatic endocrine cells from prediabetic (11-week-old)  NOD mice
compared to those in the lymphocyte-deficient  (25) NOD/SCID genetic background.
Prediabetic NOD female mice exhibit heavily infiltrated pancreatic islets, while islets
from age-matched NOD/SCID mice are infiltration-free. We confirmed these results by
quantitative  Real  Time  PCR  (qRT-PCR)  (Figure  1A)  and  found  that  pancreatic
endocrine islet cells from predibetic NOD females exhibited a dramatic reduction in
cyclin D3 mRNA expression levels compared to those from age-matched NOD/SCID
females  (1.00±0.95  vs  18.04±10.86,  respectively).  To  address  whether  cyclin  D3
expression was also downregulated at the protein level we isolated islets from 6-week-
old NOD (mild infiltration), 11-week-old NOD (heavy infiltration), 6-week-old and 11-
week-old NOD/SCID (no infiltration) mice and 11-week-old NOD/SCID T mice (non-
diabetic NOD/SCID mice that had been adoptively transferred 10 million of total spleen
cells from prediabetic NOD female donors two weeks earlier in order to promote islet
infiltration  in  these  otherwise  infiltration-free  recipients),   and  assessed  cyclin  D3
protein expression by flow cytometry (Figure 1B).  We used CD45 as a hematopoietic
marker to exclude the immune cells infiltrating islets, and the Glut-2 glucose transporter
as a β cell marker.
The cyclin D3 expression levels in β (CD45-Glut-2+) cells from 11-week-old NOD
mice  were  1.3  times  lower  than  those  in  6-week-old  NOD  mice  (77.18±9.24  vs.
7
103.3±4.89,  respectively),  and  2.3  times  lower  than  those  observed  in  age-matched
NOD/SCID mice (77.18±9.24 vs. 177.6±38.00 respectively). No significant differences
were detected between β cells from either 6 or 11 week-old NOD/SCID mice (Figure
1B).
  To  confirm  the  causal  relationship  between  islet  infiltration  and  cyclin  D3
downregulation  we  performed  adoptive  transfer  experiments  in  which  6  week-old
NODSCID mice were adoptively transferred intravenously with either 107  total spleen
cells or injected with saline solution and, two weeks later, cyclin D3 RNA expression
levels in islet endocrine cells (CD45- fraction) were assessed by qRT-PCR (Figure 1C).
An approximate 6-fold reduction in the CcnD3 mRNA expression levels was observed
upon adoptive transfer of splenocytes into NOD/SCID recipients compared to the saline
control group (1.00 ±0.608 vs. 0.165 ±0.038; respectively). Furthermore, we addressed
whether  the  cyclin  D3  protein  levels  in  pancreatic  β cells  were  also  affected  by
leukocyte infiltration in a dose-dependent manner. We found that there was a significant
inverse correlation between the cyclin  D3 protein expression levels and the dose of
NOD  splenocytes  that  were  adoptively  transferred  into  the  NOD/SCID  recipients
(Figure 1D). 
Regarding the other D-type cyclins, D1 and D2, we found that cyclin D1 mRNA
was equally expressed in pancreatic endocrine cells from both, 11 week-old NOD and
NOD/SCID  islets,  while  cyclin  D2  expression  in  NOD/SCID  endocrine  cells  was
significantly higher (around 9 times higher) than in those from age-matched NOD mice
(1.01±0.17  vs.  9.25±3.7,  respectively)  (Supplementary  Figure  1A-C).  However,
contrarily to what occurs with cyclin D3, neither cyclin D1 nor D2 mRNA expression
levels were altered in islet endocrine cells from NOD/SCID mice upon adoptive transfer
of  NOD  splenocytes  (Supplementary  Figure  1D-F).   This  result  evidences  the
9uniqueness of cyclin D3 among D-type cyclins in being the only one downregulated by
inflammation.
To  determine  whether  cyclin  D3  downregulation  hampered  the  NOD  β cell
replicative activity, we evaluated  the proliferation  rates of β cells (CD45-Glut-2+Ki67+)
from  11-week-old  NOD/SCID  mice  that  received  different  doses  of  adoptively
transferred splenocytes from NOD donors at 9 weeks of age (Figure 1E). The apparent
differences  in  β cell  proliferation  rates  among  the  experimental  groups  were  not
statistically significant.
Cyclin  D3 overexpression  protects  NIT-1  β cells  from spontaneous  and cytokine-
induced apoptosis. 
To  address  whether  cyclin  D3  overexpression  could  protect  the  NIT-1  NOD
insulinoma cell line from apoptosis upon exposure to pro-inflammatory cytokines we
stably  transfected  NIT-1  cells  with  a  plasmid  (pBSKNeoRIP-mCcnD3-Eα)  that
contained the mouse cyclin D3 cDNA under the control  of the rat  insulin promoter
(RIP) (26) and a neomycin selection marker. As a mock control, we used NIT-1 cells
transfected with the empty pBSKNeo vector.  Cyclin D3 expression was assessed by
flow cytometry in stably transfected NIT-1 cells (Supplementary Figure 2), and the cells
were assayed for early apoptosis (Supplementary Figure 2B). Interestingly, NIT-1 cells
that  overexpressed  cyclin  D3  were  more  resistant  to  both  basal  and  IL-1β-induced
apoptosis compared to the mock pBSKNeo transfectants (Supplementary Figure 2B). In
contrast, neither IFNγ nor IFNγ+ IL-1β-induced NIT-1 cell apoptosis were affected by
cyclin  D3  overexpression.  Cyclin  D3  overexpression  only  increased  NIT-1  cell
proliferation in the presence of IFNγ however, at basal condition or in the presence of
IL-1β (Supplementary Figure 2C) there was no effect. 
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Cyclin D3 deficiency enhances β cell apoptosis and diabetes in vivo, while cyclin D3
overexpression in β cells protects against both of them.
We further investigated the role of cyclin D3 in NOD β cells in vivo, to ascertain
whether  cyclin  D3  deficiency  would  enhance  β cell  apoptosis,  hence  exacerbating
diabetes, and conversely,  whether cyclin D3 overexpression in  β cells would protect
from diabetes. 
First,  we  obtained  cyclin  D3-deficient  NOD  mice  (N-KO)  (Figure  2A;
Supplementary Figure 3A; see Supplementary Figure 3B for the assessment of the anti-
mouse cyclin D3 antibody binding specificity). The lack of cyclin D3 was associated
with a smaller β cell area per islet that was nearly half the size of that in wild type (N-
WT) littermate mice (6533±1286 µm2/islet in N KO vs 13797±1437 µm2/islet in N-WT;
Figure 2B).  We also introduced the  CcnD3 null mutation into the NOD/SCID strain
(NS-KO).The deficiency in cyclin D3 in the NOD/SCID background (NS-KO) also was
associated  to  a  smaller  β cell  area  compared  to  that  exhibited  by  NS-WT  islets
(3937±478.3 in the NS-KO compared to 6100±647.5 in the NS-WT littermates) (Figure
2B). Interestingly, the  β cell area of NS-WT islets was also significantly smaller than
that observed in N-WT (6100± 647.5 in NS-WT vs. 13793± 1437 in N-WT) (Figure
2B). 
The body weight was also affected by cyclin D3 expression levels (Figure 2C and
2D). However, pancreas weight was not diminished in the NS-KO mice compared to
NS-WT littermates (Figure 2E). The pancreas to body weight ratio was significantly
augmented  in  both,  NS-HTZ (NOD/SCID  mice  heterozygous  for  the  deficiency  in
cyclin D3) and NS-KO, compared to NS-WT littermates, due to the smaller body size
exhibited by both genotypes (Figure 2F). 
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We assessed  Pancreatic  Lipase  (PL)  mRNA expression  levels  in  the  exocrine
pancreatic tissue from 8-12 week-old both NS-WT or NS-HTZ mice and we observed
that  PL  expression  was  upregulated  in  exocrine  pancreas  from  NS-HTZ  mice
(Supplementary Figure 4).
We studied the spontaneous diabetes incidence in N-KO mice (Figure 3A), and
found  that  N-KO mice  developed  exacerbated  diabetes,  characterized  by an  earlier
diabetes onset  and higher  cumulative disease incidence (89.3%) compared to N-WT
littermates (64.5%), while N-HTZ (NOD mice heterozygous for the deficiency in cyclin
D3)  presented  an  intermediate  phenotype,  characterized  by an  increased  cumulative
disease incidence (87.5%) without accelerated disease onset (Figure 3A). Furthermore,
to assess both the autoimmune cause of the diabetic phenotype and the severity of the
insulitic infiltrate, we scored the infiltration degree associated with either the N-WT or
the  N-KO genotype  in  6-week-old  mice  (Figure  3B).  We observed  that  the  N-KO
genotype, along with exhibiting the worst diabetes course (Figure 3A), also exhibited a
more severe insulitic assault (Figure 3B). No differences in  β cell proliferation were
associated with a lack of cyclin D3 expression in the β cells (Figure 3C).
In  the  absence  of  a  NOD lymphocytic  repertoire,  the  deficiency in  cyclin  D3
expression did not induce spontaneous diabetes in NOD/SCID mice (Figure 3D), thus
implying that lymphocytic infiltration triggers a mechanism(s) in addition to cyclin D3
downregulation that is also required for diabetes onset.
To exclude the possibility that cyclin D3 deficiency in the immune compartment
was responsible for the exacerbated diabetes observed in N-KO mice, we performed
adoptive transfer experiments with 10 million total splenocytes from N-KO, N-HTZ and
N-WT donor mice into NOD/SCID recipient mice (Figure 3E). The diabetes incidence
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was monitored for 16 weeks after transfer, and we observed that splenocytes from N-
KO donors were less diabetogenic than those from N-WT donors (36.4% vs. 81.6%;
Figure 3E). Therefore, cyclin D3 deficiency in the immune system did not account for
the exacerbated diabetes observed in the N-KO mice. 
To further restrict the role of cyclin D3 deficiency to β cells, we performed reverse
adoptive transfers wherein total splenocytes from NOD donors were injected into NS-
KO, NS-HTZ or NS-WT mice recipients. The diabetes incidence was monitored for 16
weeks after transfer (Figure 3F), and in accordance to our previous results, the NS-KO
mice were more susceptible to diabetes onset than their NS-WT littermates (80% vs.
59.5%, respectively), confirming that cyclin D3 expression in β cells is relevant to their
viability upon exposure to the autoimmune insult.
Since N-HTZ and N-KO exhibited very similar phenotypes, we assessed whether
cyclin D3 hemideficiency in the NS-HTZ β cells had any effect on the expression of the
other two D-type cyclins in islet cells by qRT-PCR (Supplementary Figure 5). We chose
the NOD/SCID background to avoid the insulitis occurring in the NOD background that
was likely to alter the expression results obtained. The hemideficiency of cyclin D3
caused a 6 fold reduction in cyclin D1 mRNA expression levels in islet cells (1.00 ±
0.43 in NS-WT, vs. 0.1575± 0.028 in NS-HTZ) while it  had no effect on cyclin D2
expression. 
Five transgenic NOD founder lines were produced by directly microinjecting the
RIPCcnD3Eα transgene into fertilized NOD oocytes with the goal of overexpressing
cyclin D3 in the  β cells alone. Amongst these 5 transgenic lines (6876, 6877, 6880,
6889,  and  6896),  only  founder  line  6896  exhibited  significant  cyclin  D3  protein
overexpression in the  β cells compared to transgene negative littermates (Figure 4A).
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Hence, only transgenic line 6896 was used for further experiments (N-TG: transgene
positive individuals; N-WT: transgene-negative littermates).  
No differences  were  observed  regarding  the  β cell  area  per  islet  (Figure  4B)
between the N-TG and N-WT mice. In Figure 4B the β cell areas of all the genotypes
studied  is  represented.  Cyclin  D3  and  insulin  expression  were  examined  by
immunofluorescence staining and confocal  microscopy (Figure 4C).   In  N-TG mice,
cyclin D3 was highly abundant in the cytoplasm. 
The  kinetics  of  disease  onset  was  delayed  in  N-TG  individuals,  implying  a
protective role for cyclin D3 against spontaneous diabetes (Figure 5A). There was no
significant difference either in the insulitis scores (Figures 5B) or in β cell proliferation
associated with cyclin D3 overexpression in the β cells (Figure 5C). The restoration of
cyclin  D3 expression solely in  β cells  from N-KO mice had no effect  on the body
weight (Figure 5D), but it significantly diminished the basal glycemia values (Figure
5E).
To fully confirm the causal relationship between cyclin D3 deficiency and β cell
death in T1D, we introduced the 6896 transgene into the NS-KO mice (NS-KO-TG).
This experimental approach allowed us to examine whether the restoration of cyclin D3
expression  limited  to  β cells  from  NOD/SCID  mice  fully  deficient  in  cyclin  D3
protected  them  from  adoptively  transferred  diabetes.  We  transferred  10  million
splenocytes  from NOD mice  into  individuals  with  the  NS-KO-WT and NS-KO-TG
genotypes  and  monitored  the  diabetes  incidence  (Figure  5F).  Diabetes  incidence
exhibited by NS-KO-TG mice (45.5%) was approximately half of that shown by NS-
KO-WT littermates (80%) (Figure 5F). 
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A summary of  the  cumulative  incidence  of  spontaneous  diabetes  onset  in  the
different genotypes  studied is shown in Figure 5G.  Those NOD genotypes  with the
lowest cyclin D3 expression levels in  β cells (N-KO and N-HTZ) exhibited the most
severe diabetic phenotype while the genotype with the highest cyclin D3 expression
levels (N-TG) was associated to the mildest diabetic phenotype. Based on our results,
we concluded that cyclin D3 plays a relevant role in the promotion of  β cell survival
that does not depend on changes in β cell proliferation.  
We further explored whether cyclin D3 acted to protect β cells from apoptosis. We
performed  a  TdT UTP Nick  End  Labeling  (TUNEL)  staining  assay  to  detect  late
apoptotic events in pancreatic sections from 6-week-old N-WT, N-KO and N-TG mice
(Figure 5H). We observed the highest apoptotic levels in N-KO β cells (1.6 fold increase
compared to N-WT β cells), and the lowest apoptotic rate in N-TG  β cells (1.9 fold
decrease  compared  to  N-WT  β cells).  This  finding  correlates  with  the  spontaneous
diabetes incidence exhibited by these three genotypes.
Furthermore,  because  apoptotic  cells  are  naturally  removed  by  infiltrating
phagocytes, N-KO islets should bear the highest ratio per mm2 of phagocytes compared
to the other genotypes studied. To assess the level of phagocyte infiltration in N-KO
islets, we chose as phagocyte markers Mac-3 (expressed in macrophages) and CD11b
(expressed in both types of phagocytes: macrophages and activated neutrophils and also
in  other  immune  cell  subsets  such  as  natural  killer  cells  and  dendritic  cells).  We
examined the number of CD11b+ and Mac-3+ cells per mm2 of β cell area in 6-week-old
mice with the N-WT, N-KO and N-TG genotypes (Supplementary Figure 6). We found
that, as expected,  N-KO islets exhibited the largest  Mac-3+ load, followed by N-TG
islets, while N-WT had the smallest load. The reported wide heterogeneity in cell types
15
expressing CD11b that also comprehend non-phagocytic cell subsets could explain the
lack of differences found for CD11b staining in the N-KO islets compared to N-WT
islets.  
This finding confirmed a dose-dependent role of cyclin D3 in the prevention of β
cell apoptosis.
Cyclin D3 causes a significant improvement in glucose responsiveness in vivo.
We examined the effects of cyclin D3 perturbation on glucose tolerance tests  in
vivo.  To assess the  in vivo β cell fitness in N-KO versus N-WT mice, we performed
intraperitoneal glucose tolerance tests (IPGTTs) on non diabetic 11-week-old mice. 
N-KO mice showed deficient  responses to glucose at  15 and 30 minutes post-
stimulus compared to N-WT littermates (Figure 6A). This result very probably reflects
the more advanced state of infiltration of the N-KO islets compared to those from N-
WT  littermates.  The  basal  blood  glucose  levels  in  11-week-old  N-KO  mice  were
significantly lower than those observed in the N-WT littermates (55.91±5.8 in the N-
KO, vs. 81.2±3.77 in the N-WT) (Figure 6B, upper panel), in spite of exhibiting the
same basal insulinemia values (Figure 6B, lower panel).  
We  also  tested  whether  cyclin  D3  overexpression  would  confer  an  improved
sensitivity  to  glucose  challenges  by  submitting  11-week-old  N-TG  and  N-WT
littermates to an intraperitoneal  glucose challenge (Figure 6C).  Notably,  N-TG mice
exhibited improved glucose responses compared to N-WT littermates at 15, 30, and 60
min post-stimulus, thus confirming that cyclin D3 expression leads to improved β cell
fitness. Both genotypes showed no differences in basal  glycemia values (Figure 6D,
upper  panel),  however,  N-TG  mice  exhibited  significantly  lower  basal  insulinemia
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values  compared  to  transgene  negative  littermates  (0.762±0.115  in  N-WT,  vs.
0.529±0.022 in N-TG) (Figure 6D, lower panel). 
These phenotypical differences with regard to in vivo glucose clearance observed
among the five genotypes were not attributable to differences in insulinemia values at
the glycemia measurement time points (Figures 6E and 6F), or to differences in islet
insulin  content  (Figure  6G).  We  further  pursued  an  in  vitro analysis  of  the  islet
physiology to  discriminate between pancreatic  islet  fitness  and insulin  sensitivity in
peripheral tissues.
Cyclin D3 is required for proper intracellular calcium [Ca2+]i  fluxes in  β cells  in
response to glucose challenges
We further assessed  β cell  fitness ex vivo by examining changes in the intracellular
calcium  concentrations  upon  islet  exposure  to  increasing  extracellular  glucose
concentrations. We chose islets from young mice (6-week-old) to avoid damaged islets
due to the heavy infiltration observed at older ages.
Pancreatic islets from 6-week-old N-TG, N-WT, N-HTZ and N-KO mice were isolated
and  loaded  with  5µM  Fura-2  AM  to  detect  increases  in  intracellular
[Ca2+]i concentrations (Figures 7A-7F).  Similar calcium analysis results were obtained
for N-TG and N-WT islets, which were different from those obtained for N-HTZ and N-
KO islets (Figures 7A-7F).  
At 8mM glucose, N-WT islets exhibited the expected calcium transient influx followed
by rapid oscillations. These oscillations were almost absent in islets from N-KO and N-
HTZ mice (Figure 7A and 7C). In addition, N-KO and N-HTZ islets were much less
responsive  to  8mM  glucose  than  N-WT and  N-TG  islets,  as  can  be  observed  by
comparing the Area Under the Curve (AUC) plot that represents the quantification of
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the total calcium entry into the islet (Figure 7B). No differences were observed between
AUC plots  from N-WT and N-TG islets.  At  16mM glucose,  only the  N-KO islets
exhibited abnormal changes in [Ca2+]i (Figure 7D). 
The altered responses to glucose exhibited by N-KO and N-HTZ islets at 8mM glucose
and by N-KO at 16mM glucose, measured as changes in [Ca2+]i, were not attributable to
an impaired islet sensitivity to high K+ concentrations (Figure 7E) or to differences in
the expression levels of the β cell-specific glucose transporter Glut-2 (Figure 7F). 
In  conclusion,  we have  found that  cyclin  D3 is  targeted by the autoimmune attack
against  β cells  in  T1D  and  that  cyclin  D3  plays  a  novel  dual  role  that  is
independent of its classical role in initiating cell proliferation. On one hand, cyclin
D3 promotes β cell survival by protecting β cells from apoptosis, and on the other,
it guarantees β cell metabolic fitness by regulating changes in [Ca2+]i  in response
to glucose stimulation. 
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DISCUSSION
Cyclin D3 downregulation due to inflammation
Our  results  demonstrate  that  cyclin  D3  has  a  non-redundant  and  cell  cycle-
independent  role  in  the  protection  of  β cells  against  apoptosis  and  maintenance  of
fitness that cannot be fulfilled by the other D-type cyclins expressed in these cells in the
absence of cyclin D3. 
Islet inflammation leads to cyclin D3 downregulation in pancreatic  β cells from
NOD  mice,  causing  enhanced  β cell  apoptosis  (4).  Although  there  is  an  inverse
correlation between the severity of insulitic attack and cyclin D3 expression, there were
no differences in the  β cell proliferative activity related to cyclin D3 downregulation,
presumably because cyclin D2 might compensate for cyclin D3 downregulation in cell
cycle  progression.  In  this  sense,  although  the  expression  of  cyclin  D1  mRNA is
impaired in cyclin D3-hemideficient endocrine cells, cyclin D2 mRNA is not altered,
which suggests that cyclin D2 could be the D-type cyclin responsible for keeping β cell
cycle intact in the absence of cyclin D3. Thus, the three D-type cyclins seem to follow
different regulation patterns in the NOD endocrine cells, being cyclin D3 the only D-
type cyclin negatively regulated by inflammation. 
The results  obtained  in  the  NIT-1  insulinoma model  may reflect  the  protective
mechanism exerted by cyclin D3 in β cells in vivo, by rendering them more resistant to
inflammation-induced apoptosis. The mechanism accounting for cyclin D3 protection
against  IL-1β induced  apoptosis  in  NIT-1  cells  very  probably  obeys  the  negative
interference between cyclin D3 and either NFκB,  the AP1-transcription factor, or the
MAPK signaling (27, 28).  In this case, cyclin D3 and NFκB would negatively feedback
each other, since the cyclin D3 promoter has binding sites for the NFκB transcription
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factor  (14),  and  cyclin  D3 would  hinder  the  NFκB-mediated  IL-1β signaling.  This
would  not  be  surprising,  since  cyclin  D3  has  also  been  reported  to  bind  certain
transcription factors such as PPARγ, ATF-5 factors (18, 19, 29)  or nuclear receptors
(30). 
It  is noteworthy that cyclin D3 overexpression does not protect NIT-1 cells from
IFNγ−induced apoptosis. Anyhow, the extent to which IFNγ is able to induce apoptosis
in  NIT-1  cells  is  very  limited  in  comparison  to  that  exhibited  by  IL-1β. These
observations, in agreement with what has already been described, evidence that both
cytokines signal by two different pathways to promote apoptosis, one of which, the one
triggered by IL-1β, is severely inhibited by cyclin D3, while the one related to IFNγ, is
not affected by changes in cyclin D3 expression levels. Although IFNγ signals through
the JAK2/STAT1 pathway and IL-1β through the NFκB pathway, both pathways can
crosstalk through the MAPK kinase cascade (27, 28). Moreover, both TNFα and IFNγ
have been reported to potentiate IL-1β effects on β cells (28). Signaling through IL-1β
receptor  causes  induction  of  Fas,  the  extrinsic  pro-apoptotic  pathway,  and  iNOS,
involved in β cell necrosis, amongst other genes in mouse β cells (2, 31). In addition,
IL-1β has been reported to cause β cell dysfunction (32).
We also find that cyclin D3 causes IFNγ to enhance NIT-1 cell proliferation. These
divergent actions of cyclin D3 on IL-1β (protecting from IL-1β-induced apoptosis) and
IFNγ (promoting  proliferation)  signaling  pathways  respectively,  imply  a  complex
biochemical  network in  which cyclin  D3 exerts  a  dominant role over  the otherwise
deleterious effects of these cytokines on β cells.
Cyclin D3 role in β cell viability, proliferation and immunogenicity
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Here,  we report  that  the apoptosis rates and the diabetes  incidences  for  the
different genotypes studied regarding cyclin D3 expression show parallel behaviors,
evidencing  a direct relationship between cyclin D3 expression in the  β cells and
protection against diabetes. At the same time, no changes in β cell proliferation are
observed. It has been reported that the adenoviral transfer of cyclin-D3 into human
pancreatic islets is followed by the translocation of this protein to the cell nucleus,
and subsequently  β cell  replication is  promoted (33).  We have not observed this
outcome in β cells from transgenic NOD mice overexpressing cyclin D3. A possible
explanation for these two apparently contradictory outcomes could be that most of
the overexpressed cyclin D3 in transgenic mice remains in the cytoplasm of β cells.
Hence, the sole overexpression of cyclin D3 in  β cells is not sufficient to lead to
enhanced  β cell  replication,  but  the  translocation  to  the  nucleus  is  required.
Moreover,  an  increase  in  the  expression  of  other  cell  cycle  rate-limiting  factors
distinct from cyclin D3 (e.g. Cdk4 in mice) may be required together with cyclin D3
overexpression to promote β cell proliferation.
According to our findings, cyclin D3 is not relevant for β cell replication in adult NOD
mice. However, the smaller islet size in both, NOD and NOD/SCID mice deficient in
cyclin  D3  suggests  that  cyclin  D3  would  be  involved  in  regulating  β cell  mass
generation at earlier phases of life. In both cases, cyclin D3 deficiency renders  β cells
more susceptible to either spontaneous (NOD background) or transferred (NOD/SCID
background) autoimmune attack. In this sense, the reduction in size of the target organ
may facilitate the onset of diabetes in both cases. However, the sole reduction in β cell
area  does  not  account  for  diabetes,  since  NS-KO  mice  do  not  develop  diabetes
spontaneously. 
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The loss of cyclin D3 enhances β cell apoptosis, leading to an increased need
of autoantigen engulfment by macrophages to avoid inflammation.  Furthermore, the
reported inefficient macrophage scavenger activity in the NOD strain (34, 35) may
lead to an enhanced proinflammatory environment, promoting the recruitment of a
larger number of effector immune cells to the apoptotic foci in the islets. This would
explain the higher  infiltration score observed in  pancreatic  islets  from cyclin  D3
deficient NOD mice, in spite of exhibiting a less diabetogenic immune repertoire. In
this sense, by promoting a more proinflammatory environment cyclin D3 deficiency
would yield β cells that are more immunogenic.
 Although cyclin D3 interaction with caspase-2 has been reported to enhance
apoptosis in some cell lines in a cell cycle-related manner (36) we have observed that
cyclin D3 prevents apoptosis in a cell-cycle independent fashion, thus suggesting the
existence  of  other  cyclin  D3 partners  distinct  from caspase-2  with  anti-apoptotic
action.  
Therefore, the higher apoptotic rates, enhanced proinflammatory environment and
smaller size of the target tissue would result in the exacerbation of the disease observed
in NOD mice deficient in cyclin D3. 
Cyclin D3 in β cell metabolic fitness 
In addition to higher apoptotic susceptibility, cyclin D3-deficient β cells exhibit a
reduced responsiveness to glucose stimulus, which is translated into delayed glucose
clearance in N-KO mice. No abnormalities were observed in either insulinemia or islet
insulin content in  the absence of  cyclin  D3,  implying that  other  adaptive peripheral
mechanisms  along  with  those  provided  by  cyclin  D3  are  present.  The  apparent
contradiction between the lower basal glycemia levels and impaired glucose clearance
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upon glucose challenge in the N-KO mice reflects a dichotomy in the action of cyclin
D3. On one side, cyclin D3 modulates negatively the sensitivity of peripheral tissues to
insulin (18), and on the other, cyclin D3 exerts a positive effect on glucose sensing by
pancreatic β cells. The final balance between both driving forces, sensitivity to insulin
and insulin secretion, will determine blood glucose levels. The lower insulinemia values
in mice overexpressing cyclin D3 in their islets, in spite of exhibiting normal glycemia
when compared to wild type littermates, are an intriguing outcome, since a priori the
insulin sensitivity in peripheral tissues is expected to be the same in both experimental
groups.  In  addition,  glucose  sensitivity  of  β cells  regarding  calcium fluxes  are  not
improved when cyclin D3 is overexpressed in these cells. These observations suggest
that cyclin D3, by an unknown mechanism, may exert a distal influence on peripheral
tissues when overexpressed in β cells, modulating glucose clearance. In agreement with
this supposition, NOD mice deficient in cyclin D3 that overexpress cyclin D3 limited to
β cells,  exhibit  lower  blood glucose levels (improved glucose clearance)  than NOD
mice ubiquotously deficient in cyclin D3. 
In  addition,  cyclin  D3  action  extends  beyond  the  endocrine  pancreas,  since  its
partial deficiency in the exocrine pancreas is associated to a significant upregulation of
the Pancreatic Lipase mRNA, very probably obeying a compensatory mechanism to
avoid the accumulation of triglycerides. 
Concluding remarks
  Cyclin D3, although traditionally classified as a protein involved in the cell cycle,
interacts physically with proteins that have distinct functions and structures from CDKs.
All of the evidence suggests a scenario in which the function of cyclin D3 in  β cells
would encompass roles that coordinate glucose metabolism, survival and cell replication
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in a complex manner. Further work needs to be conducted to unveil potential check-
points at which cyclin D3 intervenes to protect β cells from apoptosis and regulates their
physiology. 
In conclusion, cyclin D3 downregulation in pancreatic  β cells prior to diabetes
onset in NOD mice leads to  β cell dysfunction and death, in a cell cycle-independent
manner.  Here, we identify cyclin D3 as a key molecule involved in preserving β cell
mass  in  optimal  physiological  conditions,  highlighting the potential  implications  for
future therapeutic interventions in T1D.
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MATERIALS AND METHODS
Mice
Mice  were  housed  in  specific  pathogen-free  (SPF)  conditions.  All  animal
experimentation procedures performed in this study were overseen and approved by the
Institutional Ethical Committee for Animal Experimentation of the University of Lleida
(CEEA),  in  accordance  with  the  European  and  U.S.A.  Regulations  on  Animal
Experimentation.  All  results  involving  animal  experimentation  were  obtained  with
female  mice,  since  in  the  NOD strain,  males  exhibit  lower  diabetes  incidence  and
delayed kinetics  of  the disease in comparison to  their  female littermates (37).  Mice
homozygous for cyclin D3-deficiency were generously provided by Prof. P. Sicinski in
the mixed 129SvxC57BL/6 genetic background (22). We backcrossed these mice onto
the NOD background for 12 generations checking for Idd susceptibility loci (38). Cyclin
D3 null mutation was detected by PCR as described (22). We generated transgenic NOD
mice  by  microinjecting  the  RIP-CcnD3Eα transgene  (4.2-kb  NotI  fragment)  into
fertilized NOD oocytes (Xenogen / Taconic; NY, USA). The RIP CcnD3Eα construct
comprised  the  rat  insulin  promoter  (RIP)  (26)  and  the  murine  cyclin  D3  cDNA
fragment, a generous gift of M. Roussel (39). The progenies were analyzed for insertion
of  the  transgene  by  PCR  with  the:  Forward-RIP2,
CAAGACTCCAGGGATTTGAGGGA  and  Reverse-D3R1,
GACGCAGGACAGGTAGCGATCCAG primers. The PCR product size was 460 bp. 
Diabetes assessment, adoptive transfer experiments, and pancreatic islet isolation
were performed as previously described (38). For adoptive transfer experiments all the
spleen donors used were older than 8 weeks of age.
Immunohistochemical  analysis  of  pancreatic  infiltration  was  performed  as
previously  reported  (38).  Briefly,  paraffin  sections  were  counterstained  with
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hematoxylin & eosin (Sigma-Aldrich, St. Louis, USA) for infiltration studies (Leica,
Wetzler, Germany). To score islet infiltration the assigned values were as follows: 0 for
non-infiltrated islets, 1 for peri-insulitic lesions, 2 for intra-insular insulitis with less
than 50% of islet  area infiltrated,  and 3 for  insulitis  with more than 50% islet  area
infiltrated. A minimum of 8 sections per mouse at four different levels (>150 islets per
genotype) were examined. For each individual mouse the formula below was applied to
calculate the infiltration score, and then for each genotype the mean±SEM was plotted. 
(X islets of score 0 x 0)+ (Y islets of score 1 x1)+ (Z islets of score 2 x2)+ (W islets of score 3
x3)
                                                               (X+Y+Z+W)
Quantitative real time PCR (qRT-PCR)
Total RNA was extracted from a fraction of CD45- cells from either endocrine (islets) or
exocrine pancreas with Trizol reagent (Invitrogen, Carlsbad, CA, USA) and 500 ng of
the total  RNA in 20µL was reverse-transcribed  into  cDNA using the  iScript  cDNA
Synthesis Kit (Bio-Rad, Hercules, CA, USA). The cDNAs were used as templates for
qRT-PCR.  The  qRT-PCR  mixture  contained  5  µl  of  iTaq  Universal  Sybr  Green
Supermix (Bio-RAD), 4 µl of cDNA (diluted 1:5), and 0.5 µl each of the forward and
reverse primers in a final volume of 10 µl. Primers used for detection of mouse cyclin
D1 and D2 were those described previously in (23); for cyclin D3, the primers used
were  mCcnD3Fw-CAGTGACCGGCAGGCTTTG  and,  mCcnD3Rev-
CACTTCAGTGCCTGTGATCC; for  mouse pancreatic  lipase  the primers  used were
mPLFw-CTACCAGCTAATTACTTCAGATGC  and,  mPLRev-
CTGTGGCCAATCAGGTGGACATTG;  for  β-actin,  β-actinFw-
TGGAATCCTGTGGCATCCATGAAA  and,  β-actinRev-
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TAAAACGCAGCTCAGTAAGAGTCC.  The  qRT-PCR  procedure  was  as  follows:
95°C for 3 min; 95°C for 10 s, 63°C for for 40 cycles; and a melting curve from 65 to
95°C in a CFX 96 Real  time system (Bio-Rad,  USA) and  analyzed   Software CFX
manager 3.1 version (Bio-Rad, USA). β-actin was used as a control for normalizing the
gene expression.  The data obtained were calculated by the 2−∆∆Ct method.
Magnetic cell separation
Once  islets  were  isolated  and  disaggregated  by trypsin  digestion,  the  resulting  cell
suspension  was  incubated  with  a  purified  anti-mouse  CD45  antibody  (Becton
Dickinson, CA, USA), at 4ºC for 30 minutes, subsequently washed and incubated with
an anti-rat  secondary antibody coupled to  magnetic  beads (BioMags;  Qiagen Iberia,
Madrid, Spain) for 20 minutes at 4ºC. The magnetic separation was carried out using a
magnet following the BioMags manufacturer’s instructions (Qiagen). 
Intraperitoneal Glucose Tolerance Test (IPGTT).
After fasting for 16 h, mice were anaesthetized with sodium pentobarbital (60 mg/kg).
The mice received an intraperitoneal injection of 2 g of glucose per kg body weight.
Glycemia and insulinemia were measured at different time points after the injection.
Insulinemia was determined by ELISA (Mercodia, Uppsala, Sweden). 
Morphometric studies.
Pancreatic paraffin sections were stained for insulin (catalog nº. A0564; Dako, Glostrup,
Denmark). The  β cell area was quantified in a blinded fashion with optic microscopy
(Leica) and ImageJ software (NIH, Bethesda, MD; USA).
Western Blot Analysis
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Tissue  samples  were  homogenized  in  RIPA  buffer  containing  protease  inhibitors
(Sigma-Aldrich). SDS-PAGE was performed under reducing conditions, and cyclin D3
was detected with anti-mouse cyclin D3 (catalog nº 610280; Becton Dickinson) and
anti-β-actin (catalog nº A5316; Sigma-Aldrich).
Immunofluorescence analysis 
Paraffin sections were stained with anti-mouse cyclin D3, CD11b and Mac-3 antibodies
(catalog numbers:  610280, 01712D and, 553323 respectively, from Becton Dickinson),
anti-insulin (catalog nº.  A0564; Dako, Glostrup, Denmark),  and Hoechst  333421 for
nuclear staining (Sigma-Aldrich).
Islet insulin content. 
Islets were immersed in an acid–alcohol solution, sonicated and stored overnight at 4
°C.  After  centrifugation  and  protein  purification  from  the  supernatant,  the  insulin
content was determined by ELISA (Mercordia).
 Islet cell staining.
Isolated  islets  were  trypsinized  and  were  fixed  and  permeabilized  prior  to  cellular
staining  with  anti-mouse  Glut-2  (β cell  marker;  catalog  nº  BAM1440;  R&D,
Minneapolis,  MN, USA),  anti-mouse Ki67 (proliferation marker;  catalog nº M7248;
Dako),  anti-mouse cyclin D3, and phycoerythrin-conjugated CD45 antibodies (catalog
numbers  610280  and  553081,  respectively;  Becton  Dickinson).  Sample  data  were
acquired on a FACSCanto II flow cytometer (Becton Dickinson).
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Determination of early (Annexin V) or late (TUNEL) apoptotic events. Apoptosis
assays  were performed using the respective Apoptosis  detection  kits  (Becton
Dickinson).  For apoptosis analysis in NIT-1 cells by Annexin V staining, the
7AAD reagent was used as a cell death marker (Becton Dickinson).  
NIT-1 cell transfection.
The NIT-1 stable transfectants were selected with 0.4mg/mL of G418. For cytokine-
induced cell apoptosis, 105 cells per well were seeded into 12-well plates on day 0; on
day 1, cytokines were added at final concentrations of 50U/mL for IL-1β and 200U/mL
for IFNγ (Prospec; Passaic County, NJ, USA); on day 2, the cells were harvested and
assayed for either annexin V staining or Ki67 staining.
Recording [Ca2+]i
Freshly  isolated  islets  loaded  with  5µM Fura-2  AM (Invitrogen)  were  sequentially
perfused  with glucose  3mM, 8mM, 16mM, and  at  the  end  25mM KCl in  3mM of
glucose, and individual measurements for each islet were taken as reported before (40).
The time interval for each glucose concentration condition was 10 min. 
Statistical analysis
A Kruskal-Wallis test was used to assess overall statistical differences when more than 2
experimental groups were compared and subsequent Mann-Whitney tests were applied
to  evaluate  differences  between  pairs  of  groups.  A  linear  regression  model  was
performed to fit cyclin D3 expression levels depending on the dose of injected NOD
splenocytes. For assessing the difference between diabetes cumulative incidence curves
the  log-rank  test  was  applied.  A two-way  ANOVA test  was  used  to  analyze  the
differences in glycemia and insulinemia levels in glucose tolerance tests. All analyses
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were obtained with SPSS statistical package. Threshold for statistical significance was
set at 0.05.
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FIGURE LEGENDS
FIGURE  1.  In  NOD  mice,  cyclin  D3  mRNA  and  protein  expression  are
downregulated by islet infiltration in a dose-dependent manner, without affecting
the proliferative activity of  β cells A. Pancreatic islet cells from either 11-week-old
NOD mice (N; n=4) and 11-week-old NOD/SCID mice (NS; n=9) were extracted, and
the CD45- cell  subset  (endocrine cells) was selected by magnetic sorting to perform
qRT-PCR  analysis  to  assess  cyclin  D3  expression.  B. Pancreatic  islet  cells  were
extracted from 6- (N-6w; n=33) and 11-week-old (N-11w, n=9) NOD mice, 6-week-old
(NS-6w, n=13) NOD/SCID mice,  11-week-old (NS-11w, n=4) NOD/SCID mice,  and
11-week-old NOD/SCID mice that had received 10 million adoptively transferred NOD
total  splenocytes  at  9  weeks  of  age  (NST-11w;  n=11).  The  intensity  of  median
fluorescence (IMF from now on) of cyclin D3 staining on  β (CD45-Glut-2+) cells was
measured by flow cytometry.  All  comparisons were performed relative to the N-6w
values,  otherwise  comparisons  are  plotted  as  horizontal  lines  above  the  bars  being
statistically  different.  C. 6-week-old  NODSCID  mice  were  adoptively  transferred
intravenously with 107 total spleen cells (T; n=6) or injected with Saline Solution (S.S.;
n=7), and the endocrine cells were sorted (CD45- fraction) from the total pool of islet
cells  by  magnetic  separation.  Cyclin  D3  (CcnD3)  mRNA expression  levels  were
addressed by qRT-PCR analysis.  D. Assessment of cyclin D3 expression levels in  β
cells  from NOD/SCID mice that  were adoptively transferred with different  amounts
(x106)  of  total  splenocytes  (TSC;  numbers  of  recipient  mice  per  condition  were  as
follows: for 0, n=6; 1, n=6; 3, n=7; 5, n=8 and for 10, n=11) 2 weeks before the islet
extraction at 11 weeks of age. The IMF of cyclin D3 staining on β cells was measured
by flow cytometry.  All  comparisons were related to TSC (0).  Linear regression was
performed  according  to  the  equation  y=-101.69+4.64x  p=0.0004.  E. Proliferation
assessment in  β cells from 11-week-old NOD/SCID mice that had received adoptive
transfers of different amounts of total splenocytes two weeks before the islet extraction,
measured as percentages of CD45-Glut-2+ Ki67+ cells. The numbers of mice used per
condition were as follows: for 0, n=7; 1, n=7; 3, n=6; 5, n=4 and 10, n=9. Data are
represented as  the mean±SEM in A, B, C  and E;  in D,  the data are  plotted as  the
individual obtained values. In A the value of the N group was used as reference and set
at 1; in C the value of the S.S. group was used as reference and set at 1. * p≤0.05, **
p≤0.01. 
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Figure  2.  Generation  of  the  N-KO  mouse  model.  A. Pancreatic  islet  cells  were
isolated from 6-week-old N-WT (n=24) and N-KO (n=12) mice. The IMF of cyclin D3
staining on  β  cells  was  measured  by flow cytometry,  and  was expressed  as  the  %
relative to the IMF detected in β cells from N-KO islets, which was set as 1%. B. β cell
area per islet in 6-week-old mice (the number of islets analyzed was: N-WT, n=104; N-
HTZ, n=54; N-KO, n=58; NS-WT, n= 101; NS-KO, n=101).  C. Body weight of  12-
week-old  mice  (N-WT  n=23,  N-HTZ  n=12,  N-KO  n=9)  is  represented.  D.
Representative picture showing respective body sizes from either 6- week-old  N-KO
(left) or N-WT (right) mice individuals. E.  Pancreas weight and,  F. Pancreas to body
weight ratio of 10-12-week-old NS-WT, n=4; NS-HTZ, n=5; and, NS-KO n=4. Data are
represented as mean ± SEM in A C, E and F. Statistical comparisons are referred to the
N-WT values in  A-C, and NS-WT in  E and  F; otherwise comparisons are plotted as
horizontal  lines  above  the  bars  being  statistically  different.   *  p≤0.05,  **  p≤0.01,
***p≤0.001.  
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Figure 3.  Lack  of  cyclin  D3 expression exacerbates  T1D onset  and insulitis  by
rendering  β cells more susceptible to autoimmune attack, without altering the  β-
cell proliferation rates. A. The cumulative diabetes incidence in N-KO (n=56), N-HTZ
(n=62) and N-WT (n=63) mice was assessed. B. Pancreata from 6-week-old mice (n=4
mice  per  experimental  group)  were  extracted  and  levels  of  infiltration  scored.  C.
Proliferative activity was assessed in pancreatic β cells. The percentages of proliferating
CD45-Glut2+Ki67+ β cells from 6-week-old N-WT (n=24) and N-KO (n=10) mice were
plotted. D. The cumulative incidence of spontaneous diabetes in N-WT (n=63), NS-WT
(n=9),  NS-HTZ (n=11) and NS-KO (n=3) mice was monitored.  E. 3- to 5-week-old
NOD/SCID recipient mice were adoptively transferred with 10 million total splenocytes
from N-KO (T-N-KO; n=10),  N-HTZ (T-N-HTZ;  n=11)  or  N-WT (T-N-WT; n=26)
donors.  F. 3–5-week-old mice NS-KO (n=15),  NS-HTZ (n=44) and  NS-WT (n=37)
recipient mice were adoptively transferred with 10 million total splenocytes from NOD
donors. The cumulative incidence of adoptively transferred diabetes is plotted. Data are
shown as the mean±SEM in B and C; as the percentages of cumulative diabetic mice at
a particular time point in A, D, E, and F.  In A and D the comparisons are referred to the
N-WT group, in E to the T-N-WT group, and, in F to the NS-WT group. * p≤0.05, **
p≤0.01, ***p≤0.001.
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Figure  4.  Generation  of  NOD  mice  that  overexpress  cyclin  D3  in  β  cells
(NODRIPCcnD3). A. Pancreatic islets cells from 6-week-old  CcnD3 transgenic mice
were stained to assess cyclin D3 expression levels in β cells by flow cytometry. The
IMF of cyclin D3 staining was determined (number of different mice used per line:
6876-WT,  n=11;  6876-TG,  n=16;  6877-WT,  n=16;  6877-TG,  n=5;  6880-WT,  n=28;
6880-TG, n=21; 6889-WT, n=10; 6889-TG, n=5; 6896-WT, n=22; and 6896-TG, n=13).
B. β cell area per islet (the number of islets analyzed was: N-TG, n=94; N-WT, n=104;
N-HTZ,  n=54;  N-KO,  n=58;  NS-WT,  n=  101;  NS-KO,  n=101).  C.  Representative
immunofluorescence images of pancreatic sections from 6-week-old 6896 founder line
N-TG or N-WT mice, nuclei (blue), cyclin D3 (red), and insulin (green). The scale bar
corresponds  to  50µm.  Data  are  represented  as  the  mean±SEM  in  A  and  B. The
comparisons took as reference the values obtained in the transgene negative group for
each founder line (A) or the N-WT group (B), otherwise comparisons are plotted as
horizontal lines above the bars being statistically different. * p≤0.05, ***p≤0.001.
37
Figure  5. Cyclin D3 overexpression only in pancreatic β cells protects NOD mice
from T1D and confers protection against apoptosis and T1D to β cells from N-KO
mice. A. The cumulative diabetes incidence was monitored in N-TG (n=29) and N-WT
(n=30) mice.  B.  Pancreata from 6-week-old mice (n=4 for each, N-TG and N-WT)
were used to assess the level of infiltration. C. Islet cells from 6-week-old N-WT (n=12)
and N-TG mice (n=5) were stained to assess β cell proliferative activity; the percentages
of CD45-Glut2+Ki67+  proliferating cells  are plotted.  D. Body weight of  12-week-old
mice (N-TG n=13; N-KO-TG n=12; N-KO-WT n=9) is represented.  E. Non diabetic,
11-week-old mice (N-WT n=21; N-TG n=13; N-KO n=11; N-KO-TG n=3) were fasted
overnight, administered anesthesia, and glycemia was measured.  F. Either 3–5-week-
old, NS-WT (n=37); NS-KO-TG (n=11), or NS-KO-WT (n=15) mice were adoptively
transferred with 10 million total splenocytes from NOD donors, and diabetes onset was
monitored.   G.  Comparative  graph  summarizing  the  different  cumulative  diabetes
incidences relative to cyclin D3 expression levels in β cells (N-WT n=63; N-HTZ n=62;
N-KO n=56; N-TG n=29; NS-WT n=9; NS-HTZ n=11; and, NS-KO n=3). H. TUNEL
assessment of apoptotic β cells was performed on pancreatic sections from 6-week-old
N-KO (n= 4);  N-TG (n= 4); and N-WT (n= 4) mice,  and quantified using confocal
microscopy. The  numbers  of  TUNEL-positive  nuclei  per  insulin-positive  area  were
measured. Data are represented as mean±SEM in B, C, D, E and H; as percentages of
diabetic mice at a particular time point (cumulative diabetes incidence) in A, F and G.
In  A to  C, E, G  and H the comparisons were performed taking the N-WT values as
reference; in  D the N-TG values and in  F the NS-KO values were taken as reference
respectively, to perform statistical comparisons (otherwise comparisons are plotted as
horizontal  lines  above  the  bars  being  statistically  different).  *  p≤0.05,  **  p≤0.01,
***p≤0.001.
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Figure 6. The loss of cyclin D3 leads to impaired β-cell responses to blood glucose
in  NOD  mice,  while  cyclin  D3  overexpression  in  β cells  improves  glucose
responsiveness in vivo. Non diabetic 11-week-old N-KO (n=11), N-WT (n=23), N-TG
(n=13)  and  N-WT  (n=20)  mice  were  intraperitoneally  administered  glucose,  and
glycemia (A and C) and insulinemia (E and F) were measured at different time points.
As a negative control, a group of mice was submitted only to the anesthesia (N-WT-P)
without any glucose stimulation (n=3). A, B and E. Results are shown for the N-KO and
N-WT mice.  C, D  and F. Results are shown for the N-TG and N-WT mice.  B. Non
diabetic  11-week-old  NOD-KO  and  N-WT were  fasted  overnight  and  administered
anesthesia,  and  glycemia  (upper  panel:  N-KO  n=11;  N-WT n=21)  and  insulinemia
(lower panel: N-KO n=6; N-WT n=9) were measured.  D. Non diabetic 11-week-old N-
TG and N-WT mice were fasted overnight and administered anesthesia, and glycemia
(upper panel: N-WT, n=20; N-TG, n=13) and insulinemia (lower panel: N-WT, n=6; N-
TG,  n=7)  were  measured.  G.  Islet  insulin  content  was  measured  by  ELISA and
expressed as insulin content from a pool of 20 islets /mL. Data are represented as the
mean±SEM in A-G. All comparisons took the N-WT values as reference. * p≤0.05, **
p≤0.01, ***p≤0.001. 
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Figure 7. Cyclin D3 is required for glucose-stimulated intracellular calcium [Ca2+]i 
fluxes in β cells. Freshly isolated pancreatic islets from 6-week-old N-WT (n=20), N-
TG (n=18), N-HTZ (n=30) and N-KO (n=18) mice were loaded with 5 mM Fura-2 AM
and perfused with different glucose concentrations (3 mM, 8 mM, 16 Mm glucose and,
25 mM KCl in 3 mM of glucose) in modified Ringer’s solution. A. A representative plot
that compares the behaviors of the N-WT and N-KO islets with regard to Ca2+ influx is
shown. B.  A graph plotting the area under the curve (AUC) for a 5-min period (AUC/5)
in response to 8 mM glucose  C. Frequency of [Ca2+]i oscillations in pancreatic islets
from each genotype in response to 8 mM glucose D. Graph plotting the AUC/5 min in
response to 16 mM glucose. E. Graph plotting the AUC/5 min in response to 3 mM of
glucose and 25 mM of K+.  F. Assessment of Glut-2 expression levels in pancreatic  β
cells  by  MFI.  Data  are  represented  as  the  mean±SEM  in B-F.  All  comparisons
performed used the N-WT values as reference. * p≤0.05, ** p≤0.01. 
Supplementary  Figure  1. Cyclin  D3  is  the  only  D-type  cyclin  exhibiting
downregulation  upon  in  vivo  infiltration  of  pancreatic  islets. Upper  panel.
Pancreatic islets cells from 11-week-old NOD female mice (N, n=4) and 11-week-old
NOD/SCID female mice (NS, n=9) were isolated and the CD45- cell subset (endocrine
cells)  was  selected  by magnetic  sorting to  perform qRT-PCR analysis  to  assess  the
mRNA expression levels of each of D-type cyclin (D1 in  A; D2 in  B and D3 in  C).
Lower  panel. 6-week-old  NODSCID  female  mice  were  adoptively  transferred
intravenously with 107  total spleen cells (T; n=6) or injected with saline solution (S.S.;
n=7); two weeks later, mice were sacrificed and the endocrine cells were sorted (CD45-
fraction) from the total pool of islet cells by magnetic separation. The mRNA expression
levels for each D-type cyclin were addressed by qRT-PCR analysis ((D1 in D; D2 in E
and D3 in F).  Data are represented as the mean±SEM. * p≤0.05, ** p≤0.01. 
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Supplementary Figure 2. Cyclin D3 overexpression protects NIT-1 cells from basal
and IL-1β-induced apoptosis A. Cyclin D3 expression levels in the NIT-1 Neo cell
lines with either the empty pBSKNeo vector or the pBSKNeo vector that contained the
RIP-CcnD3 construct were examined by flow cytometry.  B. NIT-1 Neo cell line with
either the empty pBSKNeo vector or the RIP-CcnD3 construct were cultured with or
without IL-1β (50 U/mL), IFN-γ (200 U/mL) or both; the percent of cells undergoing
early apoptosis was measured as the AnnexinV+ PI- cells in each experimental group. C.
Proliferation levels were measured as the percentage of Ki67+ cells per group. In A, B
and C,  data are represented  as  the mean±SEM of 1  experiment  representative  of  6
independent  experiments.  Internal  comparisons are  related  to  the  basal  values  (stars
above  the  bars).  Comparisons  between  equivalent  treatments  for  both  types  of
transfected cells are plotted as horizontal lines above the bars. * p≤0.05, ** p≤0.01. 
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Supplementary Figure 3. Generation of the N-KO mouse model. A. Representative
immunofluorescence images of pancreatic sections from 6-week-old N-WT, N-HTZ and
N-KO mice that were stained for nuclei (blue), cyclin D3 (red), and insulin (green). The
scale  bar  corresponds  to  50  µm.  B. Tissue  samples  were loaded  in  lanes  1  to  7  as
indicated.  Cyclin D3 was detected in both upper panels using anti-mouse cyclin D3
clone  1  antibody  (PharMingen;  BD);  subsequently,  membranes  were  stripped  and
incubated with anti-β-actin antibody as a housekeeping protein. For exocrine tissue and
pancreatic lymph node samples 10 µg of protein per lane were loaded; for islets, either
human or mouse, 100 islets were loaded per lane. 
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Supplementary Figure 4. Pancreatic Lipase is upregulated in the exocrine pancreas
of NOD/SCID mice hemideficient in cyclin D3.   Exocrine pancreas of either 8-12
week-old NS-WT (n=6) or NS-HTZ female littermates (n=10) were extracted to assess
the mRNA expression levels of the Pancreatic Lipase (PL) by qRT-PCR analysis.  Data
are represented as the mean±SEM. * p≤0.05. 
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Supplementary Figure 5. Cyclin D1 expression is downregulated upon cyclin D3
hemideficiency in pancreatic islets of NOD/SCID mice.  Pancreatic islets from 8-12-
week-old NS-WT female mice (n=6) and 8-12 week-old NS-HTZ female mice (n=4),
were extracted to perform qRT-PCR analysis to assess the mRNA expression levels of
each of D-type cyclin (D1 in  A; D2 in  B and D3 in  C). Data are represented as the
mean±SEM. ** p≤0.01. 
45
Supplementary Figure 6.  The deficiency in cyclin D3 is related to an increased
phagocyte presence in pancreatic islets.  Pancreatic sections from 6-week-old N-KO
(n= 4), 6896TG (n= 4), and N-WT (n= 4) mice were stained for detection of phagocytic
cells and quantified using confocal microscopy. A. Representative immunofluorescence
images of pancreatic sections from 6-week-old N-WT, N-TG  and N-KO mice stained
for nuclei (blue), CD11b (red), and insulin (green) detection. The scale bar corresponds
to 50  µm. The numbers of  B. monocytes (CD11b+  cells) and,  C. phagocytes (Mac-3+
cells)  per  insulin-positive  area  were  determined.  Data  are  represented  as  the
mean±SEM.   All  comparisons  took  the  N-WT  values  as  reference;  otherwise
comparisons are plotted as horizontal lines above the bars being statistically different.
* ≤0.05, ***p≤0.001.
Supplementary Table 1. Previous mRNA microarray studies.
 
 Geneban
k
NOD/SCID : NOD mRNA 
ratio
Experiment ID
Accession
# Normalized values
Experiment 1
NM_00763
2 3,71
Experiment 2
NM_00763
2 2,11
average cyclin D3 2,91
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Supplementary Table 1. mRNA Microarray studies.  Two populations of mRNA from
pancreatic islet endocrine cells were compared: the first one was obtained from non
diabetic,  insulitis-affected,  11-week-old  NOD female mice,  therefore  at  the edge of
developing  T1D,  and,  the  second  one,  from  non-diabetic,  insulitis-free  11  week
NODSCID female mice. Single cell suspension from pancreatic islets from 11-week-old
NOD  and  NOD/SCID  females  respectively,  were  obtained,  stained  for  CD45-PE
(hematopoietic marker) and 7AAD (7 Amino-Actinomycin D, a marker for dead cells),
and submitted to Fluorescence Activated Cell Sorting (FACS), (Becton Dickinson), to
sort CD45- 7AAD-  (live islet endocrine cells). mRNA was isolated by the Trizol method
(Invitrogen, Carlsbad, CA, USA) from CD45- 7AAD-  cells from  both types of mice,
NOD and  NOD/SCID.  Subsequently,  cDNA synthesis  and  subtractive  hybridization
were  performed using the  PCR-Select  cDNA substraction  kit  (Clontech,  California,
USA). The substractive hybridization aimed to obtain cDNAs specifically expressed in
each  of  the  experimental  cDNA samples,  i.e.  NOD  and  NOD/SCID.   The  NOD-
enriched  and  the  NOD/SCID-enriched,  respectively,  cDNA  probes  were  used  to
hybridize  to microarray slides.  cDNA mouse microarray slides  (4.6K cDNA: 4608
mouse  cDNAs  spotted  on  a  glass  slide  in  duplicate)  were  provided  by   the  Keck
Microarray Facility  at  Yale  University  (New Haven,CT,  USA).  A full  list  of  genes
included in this microarray is available upon request to the Keck Microarray Facility at
Yale University. Hybridization of both, NOD- and NOD/SCID-enriched fluorescently
labeled probes to the glass slides was performed twice; microarray slide scanning, raw
data,  background-subtracted  data  analysis,  and,  statistical  analysis  was  done  by the
Keck Microarray Facility  at  Yale  University  (New Haven,CT,  USA) upon purchase
order.  Only those  cDNAs the expression  of  which  shifted  two fold  or  higher  were
considered as differentially expressed. In the table above a summary of the normalized
data related to cyclin D3 from both hybridization experiments performed is included. 
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